C1orf131 Inhibitors
C1orf131 inhibitors constitute a varied group of chemical compounds that target specific signaling pathways to decrease the functional activity of C1orf131. These compounds interfere with cellular processes like cell cycle progression, cell survival, proliferation, and differentiation, which are potentially regulated by C1orf131. For instance, the selective inhibition of cyclin-dependent kinases 4 and 6 by compounds such as PD 0332991 could directly impede C1orf131's role incell cycle control. Similarly, PI3K inhibitors, including both LY 294002 and Wortmannin, limit the PI3K/Akt signaling pathway, thereby reducing C1orf131's presumed involvement in critical survival and growth signaling mechanisms. MEK inhibitors like PD 98059 and U0126 specifically target the MAPK/ERK pathway, which, if associated with C1orf131, would result in diminished signaling capacity related to cellular differentiation and proliferation. Compounds such as Rapamycin that inhibit mTOR signaling could attenuate C1orf131's potential influence on protein synthesis and autophagy. Additionally, the histone deacetylase inhibitor Trichostatin A might indirectly impact C1orf131's activity by altering gene expression patterns, potentially affecting post-translational modifications or protein-protein interactions involving C1orf131.
In the realm of stress response and inflammatory process regulation, SB 203580, a p38 MAPK inhibitor, may reduce C1orf131's involvement by inhibiting this specific pathway. Similarly, inhibition of JNK by SP600125 could limit C1orf131's role in apoptosis and cell differentiation. Furthermore, the use of tyrosine kinase inhibitors like Gefitinib and Erlotinib, which target the EGFR signaling pathway, could lead to a reduced role of C1orf131 in related cellular growth and survival pathways. Sorafenib, a multi-kinase inhibitor, extends this concept by targeting various receptor tyrosine kinases that C1orf131 may be involved with, further diminishing the functional capabilities of C1orf131. The collective action of these inhibitors, by blocking the respective pathways, ensures a comprehensive diminution of C1orf131's activity within the cell, thereby inhibiting its potential regulatory roles in a multitude of cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
PD 0332991 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). C1orf131 has been implicated in the cell cycle regulation through potential interactions with CDK-cyclin complexes. Inhibition of CDK4/6 by Palbociclib would diminish C1orf131's functional involvement in cell cycle progression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). Given the role of the PI3K/Akt signaling pathway in various cellular processes, including those potentially involving C1orf131, inhibition of PI3K can lead to a reduction in C1orf131 activity related to cell survival and proliferation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a specific inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. C1orf131's function could be linked to this pathway, and by inhibiting MEK, PD98059 would diminish any C1orf131-mediated signaling involved in cell growth and differentiation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor, and the mTOR pathway has been associated with protein synthesis and autophagy, processes that C1orf131 might influence. By inhibiting mTOR, Rapamycin could diminish C1orf131's role in these cellular processes. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. It has been shown to alter chromatin structure and gene expression. By changing the expression patterns of various genes, Trichostatin A may indirectly diminish the functional activity of C1orf131 by altering its post-translational modifications or interactions with other proteins. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor. If C1orf131 is involved in stress response or inflammatory processes mediated by the p38 MAPK pathway, SB203580 would decrease C1orf131's involvement by inhibiting this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, SP600125 may diminish C1orf131's potential role in apoptosis or cell differentiation processes that are regulated by the JNK signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. Similar to LY294002, it diminishes the activity of the PI3K/AKT pathway, which could indirectly diminish the activity of C1orf131 if it is involved in this signaling cascade. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. If C1orf131 is involved in signaling pathways downstream of EGFR, Gefitinib would diminish its function related to cell proliferation and survival. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is another EGFR tyrosine kinase inhibitor. It would act similarly to Gefitinib, potentially diminishing C1orf131 activity if the protein is functionally connected to the EGFR signaling axis. | ||||||